Review Draft - BUZZ - Preview: Procter & Gamble is expected to report revenue growth and a decline in earnings per share in its financial report scheduled for Thursday.
路透社2026/10/22 09:07Reproduced Wednesday's "BUZZ" column, content unchanged
October 22 - ** On Wednesday, Procter & Gamble (PG.N) shares fell 1.3%. Investors are closely watching the company's comments on consumer demand and cost pressures, with its earnings report scheduled before Thursday's market open.
** According to London Stock Exchange Group (LSEG) forecasts, the consumer goods manufacturer's quarterly revenue is expected to rise 2% to $22.8 billion, while adjusted earnings per share are projected to fall to $1.88 from $1.99 a year ago.
** In its July report, the company forecasted (link) slower sales and profit growth for fiscal 2027, noting that both the geopolitical and economic environments are challenging.
** Analyst ratings on the stock include 12 "strong buy" or "buy" ratings, 14 "hold" ratings, and 1 "sell" rating.
** According to Trade Alert data, implied options pricing for PG suggests the stock could move 3.1% (in either direction) by this Friday; over the past eight quarters, the average move on the day of earnings was 1.7%.
** PG shares are up about 10% year-to-date, underperforming the S&P 500 Index .SPX which is up about 13%, but roughly in line with the Dow Jones Industrial Average .DJI rise.
(To aid non-native English speakers, Reuters offers automated translations of its reports into several other languages. Automated translation may contain errors or lack necessary context. Reuters does not guarantee the accuracy of the translated text and provides it solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starknet voters back research into life beyond Ethereum


BUZZ - Arcus Biosciences shares plunge due to $250 million stock offering
Rhone Ma Buys Back Shares for MYR 33,993.61